CFM
ATOS icon

Catalyst Funds Management’s Atossa Therapeutics ATOS Stock Holding History

Catalyst Funds Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,953
Closed -$49.2K – 500
2025
Q2 		$49.2K Buy
+3,953
New +$47.3K 0.01% 373

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Catalyst Funds Management's ATOS Position: Q3 2025 in Review

Catalyst Funds Management sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 3,953 shares — an estimated $49.2K sold.

Catalyst Funds Management first reported a position in ATOS in Q2 2025 and held it in 1 quarter. The position peaked at $49.2K in Q2 2025. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Catalyst Funds Management reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 3,953 Atossa Therapeutics shares in Q3 2025, an estimated $49.2K.
  • Catalyst Funds Management first reported a position in Atossa Therapeutics in Q2 2025 and held it in 1 quarter.
  • Catalyst Funds Management's Atossa Therapeutics position peaked at $49.2K in Q2 2025.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Catalyst Funds Management's 13F filing for Q3 2025, filed 12 Nov 2025.